Vaxart publishes H5N1 oral vaccine preclinical data in ferrets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. QGEN

Go back to Vaxart publishes H5N1 oral vaccine preclinical data in ferrets

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

October 8, 2026 8:40 AM EDT

Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet, today announced the publication of positive preclinical study results evaluating its adenovirus-based oral mucosal vaccine platform against Highly Pathogenic Avian Influenza (HPAI) H5N1, a pathogenic virus that poses a significant threat to public health. The complete, peer-reviewed study results, which were published... More